Skip to main content

Table 1 Different diagnoses and stages within the study group and the proportion of patients with cancer cachexia (types 1–3; see Methods)

From: Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia

Type of cancer N patients Of these cachectic I/II1,2 or related stages Of these cachectic III/IV1,2 or related stages Of these cachechtic No data about stage n female Of these cachectic n male Of these cachectic
Lymphoma 1 202 (40) 35 (17.3) 57+ 9 (15.8) 61+ 22 (36.1) 16+ 84 18 (21.4) 118 17 (14.4)
Colorectal 2 84 (16) 23 (27.4) 9 3 (33.3) 71 19 (26.8) 4 33 7 (21.2) 51 16 (31.4)
Leukaemia 3 58 (11) 7 (12.1) *   *   * 22 4 (18.2) 36 3 (8.3)
Other 2 Gastrointestinal 39 (8) 15 (38.5) 4 1 (25) 21 8 (38.1) 14 8 3 (37.5) 31 12 (38.7)
Lung 2 36 (7) 9 (25) 6 1 (16.7) 27 8 (29.6) 3 9 3 (33.3) 27 6 (22.2)
Breast 2 32 (6) 4 (12.5) 17 2 (11.8) 9 2 (22.2) 6 32 4 (12.5) 0  
Leukaemia-early stages 3,4 20 (4) 5 (25) *   *   * 13 2 (15.4) 7 3 (42.9)
Prostate* 4 (1) 1 (25) *   *   *    4 1 (25)
Others* 34 (7) 8 (23.5) *   *   * 13 5 (38.5) 21 3 (14.3)
Total 509 107 (21) * * * * * 214 46 (21.5) 295 61 (20.7)
  1. Numbers in parentheses denote the particular percentage.
  2. 1Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.
  3. +The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.
  4. 2UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.
  5. 3The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.
  6. 4Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).
  7. *The classifications for these tumour types could not be used for subgrouping.